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OBJECTIVE — Many of the metabolic beneﬁts of Roux-en-Y gastric bypass (RYGB) occur
before weight loss. In this study we investigated the inﬂuence of caloric restriction on the
improvements in the metabolic responses that occur within the 1st week after RYGB.
RESEARCH METHODS AND DESIGN — A mixed meal was administered to nine
subjectsbeforeandafterRYGB(average40.5days)andtoninematched,obesesubjectsbefore
and after 4 days of the post-RYGB diet.
RESULTS — Weight loss in both groups was minimal; the RYGB subjects lost 1.4  5.3 kg
(P  0.46) vs. 2.2  1.0 kg (P  0.004) in the calorically restricted group. Insulin resistance
(homeostasis model assessment of insulin resistance) improved with both RYGB (5.0  3.1 to
3.3  2.1; P  0.03) and caloric restriction (4.8  4.1 to 3.6  4.1; P  0.004). The insulin
response to a mixed meal was blunted in both the RYGB and caloric restriction groups (113 
67 to 65  33 and 85  59 to 65  56 nmol   l
1   min
1, respectively; P  0.05) without a
change in the glucose response. Glucagon-like peptide 1 levels increased (9.2  8.6 to 12.2 
5.5pg l
1 min
1;P0.04)andpeakedhigher(45.237.3to84.833.0pg/ml;P0.01)
in response to a mixed meal after RYGB, but incretin responses were not altered after caloric
restriction.
CONCLUSIONS — These data suggest that an improvement in insulin resistance in the 1st
week after RYGB is primarily due to caloric restriction, and the enhanced incretin response after
RYGB does not improve postprandial glucose homeostasis during this time.
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B
ariatric surgical procedures achieve
a large and sustained improvement
in insulin sensitivity and a high res-
olution rate in type 2 diabetes. The meta-
bolic beneﬁts of Roux-en-Y gastric bypass
surgery (RYGB) are observed very early
and precede substantial weight loss (1). It
has been proposed that the long-term im-
provements are related to a reduction in
fatmass(2);however,themechanismsfor
the early improvements remain uncer-
tain. The surgical bypass of the foregut
and/or rapid nutrient exposure of the dis-
talgutaltersenterokinerelease,whichhas
been proposed to result in metabolic im-
provements (3) and in particular glucose
homeostasis. However, caloric restriction
in the absence of weight loss has meta-
bolic beneﬁts (4) and could also contrib-
ute to the early improvements in glucose
homeostasis.
The incretins, namely glucagon-like
peptide 1 (GLP-1) and gastric inhibitory
peptide(GIP),areguthormonesthatcon-
tribute to postprandial insulin secretion
(5). RYGB augments GLP-1 secretion,
whereas its impact on GIP is less consis-
tent (3). In contrast, bariatric procedures
that induce weight loss by caloric restric-
tion in the absence of intestinal bypass,
such as adjustable gastric banding, do
not alter postprandial incretin levels (3).
Ghrelin is another enterokine that has a
primary role in appetite stimulation but
also has glucose and insulin modulatory
effects (6). The presence of an acyl group
is considered necessary for biological ac-
tivity of ghrelin, although the desacyl
form probably has biological functions as
well (7). Ghrelin levels are abnormally
low in obese individuals and remain sup-
pressed after RYGB, whereas weight loss
bydietenhancesghrelinlevels(8).Leptin
and adiponectin, adipocyte-derived hor-
mones, are thought to be mediators of
weight-related improvements in insulin
resistance.Theconcentrationsofthesehor-
mones are aberrant in obesity and normal-
izeafterRYGB.Arecentstudyindicatedthat
5% weight loss by consumption of a hy-
pocaloric diet (40% energy restriction) is
required to favorably change circulating
adipokines and metabolic parameters (9).
A limited number of reports have di-
rectly compared the contribution of duo-
denal bypass versus caloric restriction on
enterokine responses and hormone levels
after RYGB (10–12). These studies all in-
corporated moderate weight loss (10
kg) and were conducted 2–4 weeks post-
operatively.Inthepresentstudy,wecom-
pared the immediate, weight loss–
independent effects of RYGB and caloric
restriction on fasting hormone levels and
meal-stimulated enterokine release.
RYGB were evaluated within the 1st week
after surgery, and a matched group of
subjectswereevaluatedafter4daysofthe
equivalent post–bariatric surgery diet.
RESEARCH DESIGN AND
METHODS— RYBG subjects were re-
cruited from the Center for Surgical
Weight Loss at Vanderbilt University
MedicalCenterafterapprovalforsurgery.
Diet control were matched to the surgery
group(Table1)forage(P0.37),weight
(P  0.09), diabetes status and duration
(P  0.80), and A1C (P  0.56). All
subjects provided written, informed
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study protocol was approved by the
Vanderbilt University Institutional Re-
view Board.
Subjects were studied at baseline and
then after RYGB (surgery group) or after
caloric restriction (diet group). After the
baseline study, subjects in the surgery
group underwent either open or laparo-
scopic RYGB (13). The average time for
the postoperative study was 4  0.5 days
(range 2–7 days). The diet group was
studied after 4 days of caloric restriction
that replicated the post-RYGB diet. The
diet consisted of 2.5 liters of ﬂuid/day for
3 days; the 1st day included water only,
followedbywaterandsugar-freeclearliq-
uids (e.g., gelatin, juices, and/or broths
equivalent to 200–300 kcal/day) on days
2 and 3. For each study visit, subjects
were admitted after a 12-h overnight fast
for measurement of fasting and meal-
induced metabolic and hormonal re-
sponses. Blood samples were collected
from a heated forearm vein at 0700 h
(time 0), immediately after completion of
a meal (time 20), and every subsequent
hour for 4 h. Subjects were asked to take
15–20 min to complete the meal to ac-
count for the reduced stomach capacity
after RYGB. The meal was a standardized
250-kcal liquid mixed-meal containing
40 g carbohydrates, 6 g fat, and 9 g pro-
tein (8 oz of Ensure).
Sample collection and analysis
Blood was collected in chilled EDTA
tubes and immediately centrifuged, and
plasma was stored at 80°C until analy-
sis.Glucosewasmeasuredviatheglucose
oxidase method (Beckman glucose ana-
lyzer). The plasma designated for GLP-1
measurement was supplemented with
aprotinin (1,000 kIU/ml) and dipeptidyl
peptidase 4 inhibitor (20 l/ml plasma).
Plasma designated for acylated ghrelin
measurement was treated with 1 N hy-
drochloric acid (50 l/ml plasma) and
phenylmethylsulfonyl ﬂuoride (0.1
mg/ml plasma). Plasma insulin, leptin,
adiponectin, and active GLP-1 were mea-
sured using multiplex immunoassays
(Luminex xMAP). Total (acylated and
desacyl) and acylated ghrelin were deter-
mined by radioimmunoassay. Plasma
concentrations of total GIP were mea-
sured by enzyme-linked radioimmunoas-
say.A1Cwasassayedusinghigh-pressure
liquid chromatography.
Calculations
The homeostasis model assessment of
insulin resistance index (HOMA-IR) is
derived from the inverse of insulin
sensitivity based on Levy’s nonlinear
computer model (14). Total area under
thecurve(AUC)wascalculatedaccording
to the trapezoidal rule in GraphPad Prism
(version 5.02).
Statistical analyses
The Wilcoxon signed rank test was per-
formed to compare data from the same
subjects. The nonparametric Mann-
Whitney test was used for comparisons
between RYGB and diet groups. All anal-
yses were performed in R 2.6.2 (www.
r-project.org). Data are means  SD, ex-
cept for graphs which are presented as
means  SEM.
RESULTS
Weight loss
RYGB subjects lost 1.4  5.3 kg or 1.0 
3.4% of initial body weight (P  0.46) in
the 1st week postoperatively. Caloric-
restricted control subjects lost 2.2  1.0
kg or 2.2  1.0% of initial body weight
(P  0.004). Comparison of the weight
changes with RYGB and diet was not sig-
niﬁcant (P  0.09) (Table 2).
Fasting measures of insulin
resistance
Within1weekafterRYGB,fastingglucose
levels were similar to preoperative levels
(6%; P  0.14); however, a decrease in
insulin levels was observed (25%; P 
0.04). HOMA-IR also decreased by 25%
(P  0.03). Diet control subjects exhib-
ited a disparate decrease in glucose levels
(20%;P0.004)butasimilardecrease
infastinginsulinlevels(27%;P0.07)
and improvement in the HOMA-IR index
(30%; P  0.004). Changes in
HOMA-IR with RYGB and diet were not
different (P  0.45) (Table 2).
Fasting levels of enterokines and
adipokines
Fasting plasma levels of GLP-1 and GIP
werenotalteredeitherbyRYGB(P0.65
and 0.16, respectively) or after caloric re-
striction (P  0.73 and 0.13, respec-
tively). On the other hand, there were
decreases in the fasting levels of acylated
(21%; P  0.03) and total ghrelin
(20%; P  0.05) after RYGB, with no
changes in the caloric-restricted group
Table 1—Baseline subject characteristics
RYGB Diet
n 99
Age (years) 41.1  11.5 46.6  6.7
Sex (male/female) 3/6 2/7
Weight (kg) 153.2  32.2 127.0  36.5
Type 2 diabetes (yes/no) 5/4 4/5
Diabetes duration (years) 3.7  4.7 2.6  1.5
A1C (%) 6.5  1.3 6.2  1.0
Data are means  SD or count. All comparisons between groups were nonsigniﬁcant (P  0.05).
Table 2—Early effects of RYGB and short-term diet restriction on body weight and fasting
metabolic parameters
Before RYGB After RYGB Before diet After diet
Weight (kg) 153.2  32.2 151.8  33.1 127.0  36.5 124.2  36.5*
BMI (kg/m
2) 51.9  6.0 51.4  6.6 44.2  9.9 43.2  10.0*
Glucose (mmol/l) 6.4  1.5 6.0  1.8 6.8  1.8 5.4  1.1*
Insulin (pmol/l) 236  159 155  102* 220  196 178  217
HOMA-IR 5.0  3.1 3.3  2.1* 4.8  4.1 3.6  4.1*
GLP-1 (pg/ml) 34.9  32.4 36.5  32.6 39.4  14.9 39.3  32.8
GIP (pg/ml) 58.0  31.6 42.4  21.1 53.3  29.0 33.7  25.5
Leptin (ng/ml) 72.4  15.3 49.5  15.1* 61.1  30.6 38.0  21.9
Adiponectin (g/ml) 7.3  3.0 6.4  2.0 4.5  2.6 4.7  2.6
Acylated ghrelin (pg/ml) 68.2  33.6 48.5  26.9* 34.7  23.5 26.1  20.2
Total ghrelin (pg/ml) 585  272 414  107 623  205 559  268
Data are means  SD. *P  0.05 compared with baseline within each group (RYGB or Diet).
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clined 1 week after RYGB (31%; P 
0.004) and after caloric restriction
(26%; P  0.05), whereas adiponectin
levels were not altered in either group
(P  0.1) (Table 2).
Metabolic response to a mixed meal
RYGB did not result in differences in the
glucose AUC (P  0.13) or peak glucose
levels (P  0.21) achieved after a mixed
meal. The insulin response was reduced
after RYGB, evidenced by decreases in
AUC (P  0.004) and peak levels of insu-
lin (P  0.02). Conversely, there were in-
creases in the AUC (P  0.04) and peak
(P  0.01) GLP-1 levels postoperatively.
Whereas the AUC and peak levels of GIP
were not altered in response to a mixed
meal after RYGB, the peak in GIP oc-
curred earlier. Despite a decrease in the
AUC and nadir for total ghrelin in the
early postoperative period (P  0.004 for
both), ghrelin remained at fasting levels
throughout the study (Fig. 1, Table 3).
The subjects who underwent caloric
restriction similar to that for the subjects
undergoing RYGB displayed similar
changes in meal-stimulated glucose and
insulin release after the diet; the AUC
(P  0.13) and peak (P  0.34) glucose
concentrations did not change and the
AUC (P  0.02) and peak (P  0.04)
insulin concentrations decreased. Al-
thoughtheAUCforinsulinwasdecreased
in both the RYGB and diet groups, the
change in the RYGB group was greater
(P  0.04). Caloric restriction alone did
not induce any changes in enterokine re-
sponses to a mixed meal (all P  0.05),
with the exception of a decreased nadir in
ghrelin release after diet (P  0.05). In-
terestingly, caloric restriction altered the
pattern of ghrelin release. At baseline,
ghrelin levels did not vary after the mixed
meal similar to that in the RYGB subjects;
however, after the diet, ghrelin release
was suppressed after the mixed meal fol-
lowed by a steady increase in ghrelin re-
lease above fasting levels.
CONCLUSIONS — It is well estab-
lished that RYGB is effective in improving
insulin resistance and ameliorating type 2
diabetes. The beneﬁcial metabolic effects
of RYGB were initially attributed to the
substantial weight reduction achieved
withsurgery;however,subsequentinves-
tigations revealed an improvement in in-
sulin sensitivity at 6 days after RYGB
without appreciable weight loss (15). We
have conﬁrmed these ﬁndings by demon-
Figure 1—Metabolic responses during a mixed-meal before and after RYGB and diet. Blood was
drawn before (time 0), immediately after the ingestion of a mixed-meal (time 20), and every
subsequent hour for 4 h. Plasma levels of glucose (A), insulin (B), GLP-1 (C), GIP (D), and total
ghrelin(E)weremeasuredateachtimepointatbaseline(F)and4daysafterRYGB( )or3days
after a post–bariatric surgery diet ( ). Data are means  SEM.
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sensitivity (HOMA-IR) within 1 week af-
terRYGBbeforeanyapparentweightloss.
Interestingly, obese subjects, albeit with a
nonsigniﬁcantly lower body weight, who
consumed a post–bariatric surgery liquid
diet for 4 days replicated the improved
insulin sensitivity observed in the RYGB
subjects. The parallel improvements oc-
curred with minimal noticeable differ-
ences in weight loss between the two
groups. HOMA-IR is a fasting measure of
whole-body insulin resistance that has
been shown to correlate with other dy-
namic measures of insulin sensitivity in
obesesubjects,suchasthehyperinsuline-
mic-euglycemic clamp (16). Such studies
suggest that a short duration, very-low-
calorie diet can reduce hepatic glucose
production (17) and improve skeletal
muscle insulin sensitivity (4). Our data
demonstrate that the improvement in in-
sulin sensitivity, as measured by HOMA-
IR, precedes appreciable weight loss and
islargelyachievedwithcaloricrestriction.
However, we must consider the possibil-
ity that the immediate improvements in
insulin sensitivity after RYGB could have
been blunted consequent to the associ-
ated stress/inﬂammatory responses of
surgery, thus masking a greater improve-
ment in insulin sensitivity with RYGB
than with caloric restriction.
Fasting levels of GLP-1 have been re-
ported to remain stable 2–10 weeks after
RYGB (1,11,18,19), consistent with our
current observations within the 1st post-
operative week. Our data show increases
in peak GLP-1 levels and total GLP-1 re-
lease after ingestion of a mixed meal 1
week after RYGB, in agreement with pre-
vious short-term follow-up investigations
(11,19–21).ThisincreaseinGLP-1could
not be attributed to the restrictive nature
of the surgical procedure, because the ca-
loric-restricted diet group did not show
enhanced an GLP-1 release in response to
themixedmeal.TheﬁndingswithGIPare
novel; GIP is released sooner but not to a
greater extent with a meal within the 1st
week after RYGB. Laferre `re et al. (11) and
Camposetal.(10)comparedincretinlev-
els in two groups of subjects after a 10-kg
weight loss via RYGB or diet and reported
an increase in GLP-1 only after RYGB;
theirﬁndingsforGIPweredisparate,with
one reporting an increase (11) and the
other reporting no change (10). Our re-
sults, however, show altered incretin re-
leaseafterRYGBbeforesubstantialweight
loss. The proposed mechanism of en-
hancedincretinreleaseafterRYGBismost
likely related to the increased and more
rapid nutrient stimulus to the intestinal
neuroendocrine cells.
The effects of the changes in incretin
levels on the improved metabolic re-
sponses after RYGB remain controversial.
In our study, the observed increase in
GLP-1 and shift to an earlier GIP peak
within 1 week after RYGB was accompa-
nied by improved insulin sensitivity,
whereas the improvement in insulin sen-
sitivity after caloric restriction occurred
without alterations in either GLP-1 or
GIP. Thus, the improvements in insulin
sensitivity in our study are unlikely to be
duetoalteredincretin-inducedinsulinre-
lease but rather to the caloric restriction.
In fact, in both surgical and caloric-
restricteddietgroupsweobservedsimilar
decreases in insulin release (Fig. 1) ac-
companied by improved insulin sensitiv-
ity. These ﬁndings contrast with previous
reports of either no early changes in insu-
lin release (10) or an increase in insulin
release (11) after RYGB. The discrepancy
with our ﬁndings may be related to the
associated losses (10 kg) in body weight
in these studies (10,11). In addition,
GLP-1 could exert extrapancreatic effects
on improving insulin sensitivity (22),
which in our RYGB group could have
been blunted as a result of the associated
inﬂammatory responses immediately af-
ter surgery. Lastly, perhaps the improved
GLP-1 response in the 1st week after
RYGB is not robust enough to elicit in-
creased insulin secretion and glucose-
lowering effects and may take longer to
exert such effects.
Levels of the orexiogenic hormone
ghrelin are diminished in obesity (23),
perhaps indicating a positive energy bal-
ance. The short-term effect of RYGB on
fasting total ghrelin is controversial. We
observed 20% decreases in fasting levels
of acylated and total ghrelin within 1
week after RYGB; these are consistent
with previously reported decreases in
fasting total ghrelin at 6 weeks (24) but
different from another report showing no
change 1 month after RYGB (12).
Whether the decreased levels of acylated
and total ghrelin levels play a role in the
improvement in insulin sensitivity after
RYGB remains to be determined. Vester-
gaard et al. (6) demonstrated that exoge-
nous infusion of a pharmacological dose
ofacyl-ghrelinacutelyinducedinsulinre-
sistance independent of growth hormone
and cortisol.
Alterationsinadipokines,suchaslep-
tin and adiponectin, after RYGB have
been attributed to fat mass loss and are
responsible for the long-term improve-
ments in insulin resistance (2). The simi-
larities in the decrease in plasma leptin in
the RYGB and diet groups suggest that
this immediate change in leptin after sur-
gery can be accounted for by caloric re-
striction. A similar ﬁnding was reported 1
month after RYGB and diet, coinciding
with a 10-kg weight loss (12). The stable
adiponectin concentrations during ca-
loric restriction via RYGB and diet could
indicate dissociation in the regulation of
these two adipokines between nutrient
exposure and fat mass.
In summary, our present data suggest
thatcaloricrestrictionwithoutsubstantial
weight loss is of primary importance in
the rapid improvement of insulin sensi-
tivity within the 1st week after RYGB.
Early alterations in the incretin response
canbeattributedtothesurgery;however,
the enhanced incretin response does not
seem to have any additional beneﬁt be-
yond caloric restriction on glucose ho-
meostasis and insulin sensitivity. It is
important to note that our cohorts of
obese subjects were balanced for type 2
Table 3—Metabolic responses to a mixed-meal before and after RYGB and diet
Before RYGB After RYGB Before diet After diet
Glucose AUC (mmol   l
1   min
1) 1,829  510 1,714  568 1,966  641 1,637  297
Peak glucose (mmol/l) 8.4  2.1 7.9  2.5 9.4  2.6 8.2  1.5
Insulin AUC (mmol   l
1   min
1) 113  67 65  33* 85  59 65  56*
Peak insulin (pmol/l) 742  347 485  307* 532  287 406  307*
GLP-1 AUC (pg   l
1   min
1) 9.2  8.4 12.2  5.5* 10.2  5.9 11.6  6.4
Peak GLP-1 (pg/ml) 45.2  37.3 84.8  33.0* 58.8  43.2 57.2  28.4
GIP AUC (pg   l
1   min
1) 28.7  12.3 23.5  8.6 29.5  13.5 30.1  13.8
Peak GIP (pg/ml) 227  115 193  111 235  128 228  105
Ghrelin AUC (pg   l
1   min
1) 145  53 112  36* 162  58 142  52
Nadir ghrelin (pg/ml) 456  165 341  84* 543  217 393  201
Data are means  SD. *P  0.05 compared with baseline within each group (RYGB and diet).
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were similar at baseline (except for
HOMA-IR, which was higher in the sub-
jects with type 2 diabetes) and changed
similarly after intervention. Further in-
vestigations in the immediate postopera-
tive period with more dynamic measures
of insulin resistance are also warranted to
determine the mechanisms/site of im-
provedinsulinsensitivity,alongwithadi-
rect assessment of the incretin effect on
insulin production.
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